Bad Precedent? Plan B Rx/OTC Labeling May Have Implications For Existing OTCs ­– NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Nonprescription drugs, such as aspirin and ibuprofen, could be reevaluated if Barr chooses simultaneous Rx/OTC marketing of levonorgestrel at the same dose for both populations.
You may also be interested in...
Plan B OTC Submission Deemed "Not Approvable"
Barr will have to detail a mechanism for drugstores to screen women less than 16 years of age for nonprescription use of the emergency contraceptive. FDA's decision goes against the recommendation of its advisory panels.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.